By Will Feuer
Insulin transportation strategy shaper Insulet Corp. said it issued a voluntary aesculapian instrumentality correction announcement for its Omnipod Dash Personal Diabetes Manager, and expects to publication a complaint of $35 cardinal to $45 million, mostly successful the 3rd quarter, arsenic a result.
The aesculapian instrumentality correction announcement is related to the Omnipod Dash PDM battery, the institution said. It doesn't impact Insulet's Omnipod Dash Pods, the Omnipod Insulin Management System oregon the Omnipod 5 Automated Insulin Delivery System, the institution said.
The complaint is expected to mostly impact the outgo of gross for the 3rd quarter, with the remainder impacting operating expenses successful the 4th quarter, the institution said.
Shares fell little than 1% to $220 successful premarket trading.
Write to Will Feuer astatine Will.Feuer@wsj.com
/cdn.vox-cdn.com/uploads/chorus_asset/file/24020034/226270_iPHONE_14_PHO_akrales_0595.jpg)
English (US)